Safety of regadenoson stress testing in patients with pulmonary hypertension

Victor M. Moles; Thomas Cascino; Ashraf Saleh; Krasimira Mikhova; John J. Lazarus; Michael Ghannam; Hong J. Yun; Matthew Konerman; Richard L. Weinberg; Edward P. Ficaro; James R. Corbett; Vallerie V. McLaughlin; Venkatesh L. Murthy

doi:10.1007/s12350-016-0734-6

Safety of regadenoson stress testing in patients with pulmonary hypertension

Victor M. Moles^*, Thomas Cascino, Ashraf Saleh, Krasimira Mikhova, John J. Lazarus, Michael Ghannam, Hong J. Yun, Matthew Konerman, Richard L. Weinberg, Edward P. Ficaro, James R. Corbett, Vallerie V. McLaughlin, Venkatesh L. Murthy

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Objectives: We sought to determine the safety of regadenoson stress testing in patients with PH. Background: PH is increasingly recognized at more advanced ages. As many as one-third of patients with PH have coronary artery disease. Because of their physical limitations, patients with PH are unable to adequately exercise. Regadenoson can potentially have an adverse impact due to their tenuous hemodynamics. Current guidelines suggest performing a coronary angiography in patients with PH who have angina or multiple coronary risk factors. Methods: We identified 67 consecutive patients with confirmed PH by catheterization (mean PA > 25 mmHg not due to left heart disease) who underwent MPI with regadenoson stress. Medical records were reviewed to determine hemodynamic and ECG response to regadenoson. Results: No serious events occurred. Common side effects related to regadenoson were observed, dyspnea being the most common (70.6%). No syncope occurred. Heart rate increased from 74.6 ± 14 to 96.3 ± 18.3 bpm, systolic blood pressure increased from 129.8 ± 20.9 to 131.8 ± 31 mmHg, and diastolic blood pressure decreased from 77.1 ± 11.4 to 72.9 ± 15.3 mmHg. There was no ventricular tachycardia, ventricular fibrillation, or second- or third-degree atrioventricular block. Conclusion: Regadenoson stress MPI appears to be well tolerated and safe in patients with PH.

Original language	English (US)
Pages (from-to)	820-827
Number of pages	8
Journal	Journal of Nuclear Cardiology
Volume	25
Issue number	3
DOIs	https://doi.org/10.1007/s12350-016-0734-6
State	Published - Jun 1 2018

Funding

Cardiovascular Center, University of Michigan, 2nd Floor CVC / SPC 5853, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-5853; [email protected] Funding No grants, contracts, or other forms of financial support were used in this study. 1071-3581/$34.00 Copyright © 2016 American Society of Nuclear Cardiology.

Keywords

Pulmonary hypertension
coronary artery disease
pulmonary arterial hypertension
regadenoson
stress test

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12350-016-0734-6

Cite this

@article{a713f57354d944549845c26c6c119356,

title = "Safety of regadenoson stress testing in patients with pulmonary hypertension",

abstract = "Objectives: We sought to determine the safety of regadenoson stress testing in patients with PH. Background: PH is increasingly recognized at more advanced ages. As many as one-third of patients with PH have coronary artery disease. Because of their physical limitations, patients with PH are unable to adequately exercise. Regadenoson can potentially have an adverse impact due to their tenuous hemodynamics. Current guidelines suggest performing a coronary angiography in patients with PH who have angina or multiple coronary risk factors. Methods: We identified 67 consecutive patients with confirmed PH by catheterization (mean PA > 25 mmHg not due to left heart disease) who underwent MPI with regadenoson stress. Medical records were reviewed to determine hemodynamic and ECG response to regadenoson. Results: No serious events occurred. Common side effects related to regadenoson were observed, dyspnea being the most common (70.6\%). No syncope occurred. Heart rate increased from 74.6 ± 14 to 96.3 ± 18.3 bpm, systolic blood pressure increased from 129.8 ± 20.9 to 131.8 ± 31 mmHg, and diastolic blood pressure decreased from 77.1 ± 11.4 to 72.9 ± 15.3 mmHg. There was no ventricular tachycardia, ventricular fibrillation, or second- or third-degree atrioventricular block. Conclusion: Regadenoson stress MPI appears to be well tolerated and safe in patients with PH.",

keywords = "Pulmonary hypertension, coronary artery disease, pulmonary arterial hypertension, regadenoson, stress test",

author = "Moles, \{Victor M.\} and Thomas Cascino and Ashraf Saleh and Krasimira Mikhova and Lazarus, \{John J.\} and Michael Ghannam and Yun, \{Hong J.\} and Matthew Konerman and Weinberg, \{Richard L.\} and Ficaro, \{Edward P.\} and Corbett, \{James R.\} and McLaughlin, \{Vallerie V.\} and Murthy, \{Venkatesh L.\}",

note = "Publisher Copyright: {\textcopyright} 2016, American Society of Nuclear Cardiology.",

year = "2018",

month = jun,

day = "1",

doi = "10.1007/s12350-016-0734-6",

language = "English (US)",

volume = "25",

pages = "820--827",

journal = "Journal of Nuclear Cardiology",

issn = "1071-3581",

publisher = "American Society of Nuclear Cardiology",

number = "3",

}

TY - JOUR

T1 - Safety of regadenoson stress testing in patients with pulmonary hypertension

AU - Moles, Victor M.

AU - Cascino, Thomas

AU - Saleh, Ashraf

AU - Mikhova, Krasimira

AU - Lazarus, John J.

AU - Ghannam, Michael

AU - Yun, Hong J.

AU - Konerman, Matthew

AU - Weinberg, Richard L.

AU - Ficaro, Edward P.

AU - Corbett, James R.

AU - McLaughlin, Vallerie V.

AU - Murthy, Venkatesh L.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Objectives: We sought to determine the safety of regadenoson stress testing in patients with PH. Background: PH is increasingly recognized at more advanced ages. As many as one-third of patients with PH have coronary artery disease. Because of their physical limitations, patients with PH are unable to adequately exercise. Regadenoson can potentially have an adverse impact due to their tenuous hemodynamics. Current guidelines suggest performing a coronary angiography in patients with PH who have angina or multiple coronary risk factors. Methods: We identified 67 consecutive patients with confirmed PH by catheterization (mean PA > 25 mmHg not due to left heart disease) who underwent MPI with regadenoson stress. Medical records were reviewed to determine hemodynamic and ECG response to regadenoson. Results: No serious events occurred. Common side effects related to regadenoson were observed, dyspnea being the most common (70.6%). No syncope occurred. Heart rate increased from 74.6 ± 14 to 96.3 ± 18.3 bpm, systolic blood pressure increased from 129.8 ± 20.9 to 131.8 ± 31 mmHg, and diastolic blood pressure decreased from 77.1 ± 11.4 to 72.9 ± 15.3 mmHg. There was no ventricular tachycardia, ventricular fibrillation, or second- or third-degree atrioventricular block. Conclusion: Regadenoson stress MPI appears to be well tolerated and safe in patients with PH.

AB - Objectives: We sought to determine the safety of regadenoson stress testing in patients with PH. Background: PH is increasingly recognized at more advanced ages. As many as one-third of patients with PH have coronary artery disease. Because of their physical limitations, patients with PH are unable to adequately exercise. Regadenoson can potentially have an adverse impact due to their tenuous hemodynamics. Current guidelines suggest performing a coronary angiography in patients with PH who have angina or multiple coronary risk factors. Methods: We identified 67 consecutive patients with confirmed PH by catheterization (mean PA > 25 mmHg not due to left heart disease) who underwent MPI with regadenoson stress. Medical records were reviewed to determine hemodynamic and ECG response to regadenoson. Results: No serious events occurred. Common side effects related to regadenoson were observed, dyspnea being the most common (70.6%). No syncope occurred. Heart rate increased from 74.6 ± 14 to 96.3 ± 18.3 bpm, systolic blood pressure increased from 129.8 ± 20.9 to 131.8 ± 31 mmHg, and diastolic blood pressure decreased from 77.1 ± 11.4 to 72.9 ± 15.3 mmHg. There was no ventricular tachycardia, ventricular fibrillation, or second- or third-degree atrioventricular block. Conclusion: Regadenoson stress MPI appears to be well tolerated and safe in patients with PH.

KW - Pulmonary hypertension

KW - coronary artery disease

KW - pulmonary arterial hypertension

KW - regadenoson

KW - stress test

UR - http://www.scopus.com/inward/record.url?scp=84997770350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997770350&partnerID=8YFLogxK

U2 - 10.1007/s12350-016-0734-6

DO - 10.1007/s12350-016-0734-6

M3 - Article

C2 - 27896702

AN - SCOPUS:84997770350

SN - 1071-3581

VL - 25

SP - 820

EP - 827

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

IS - 3

ER -

Safety of regadenoson stress testing in patients with pulmonary hypertension

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this